We previously reported that vaccine-elicited Env V1V2 IgG3 correlated with decreased HIV-1 risk in RV144 [7], and in the HVTN 505 efficacy trial (DNA prime/rAd5 boost), Env IgG3 binding breadth also correlated with reduced risk of infection [51]. The gene discussed is IGHG3; the disease is infection.